| Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women OE Iversen, MJ Miranda, A Ulied, T Soerdal, E Lazarus, ... Jama 316 (22), 2411-2421, 2016 | 243 | 2016 |
| Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. A Varga, SA Piha-Paul, PA Ott, JM Mehnert, D Berton-Rigaud, ... Journal of Clinical Oncology 33 (15_suppl), 5510-5510, 2015 | 188 | 2015 |
| 525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028 YJ Bang, T Doi, F De Braud, S Piha-Paul, A Hollebecque, ARA Razak, ... European Journal of Cancer 3 (51), S112, 2015 | 171 | 2015 |
| Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028. PA Ott, MEE Fernandez, S Hiret, DW Kim, RA Moss, T Winser, S Yuan, ... Journal of Clinical Oncology 33 (15_suppl), 7502-7502, 2015 | 126 | 2015 |
| Statistical design and considerations of a phase 3 basket trial for simultaneous investigation of multiple tumor types in one study C Chen, X Li, S Yuan, Z Antonijevic, R Kalamegham, RA Beckman Statistics in Biopharmaceutical Research 8 (3), 248-257, 2016 | 67 | 2016 |
| Abstract CT103: Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028 EW Alley, LR Molife, A Santoro, K Beckey, S Yuan, JD Cheng, B Piperdi, ... Cancer research 75 (15_Supplement), CT103-CT103, 2015 | 64 | 2015 |
| Pembrolizumab (MK-3475) for patients (pts) with advanced esophageal carcinoma: Preliminary results from KEYNOTE-028. T Doi, SA Piha-Paul, SI Jalal, H Mai-Dang, S Yuan, M Koshiji, I Csiki, ... Journal of Clinical Oncology 33 (15_suppl), 4010-4010, 2015 | 60 | 2015 |
| 502 Pembrolizumab (MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028 BH O'neil, J Wallmark, D Lorente, E Elez, J Raimbourg, C Gomez-Roca, ... European Journal of Cancer 3 (51), S103, 2015 | 30 | 2015 |
| Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study C Hsu, SH Lee, S Ejadi, C Even, R Cohen, C Le Tourneau, J Mehnert, ... Ann Oncol 26, 2015 | 27 | 2015 |
| Pembrolizumab for ED SCLC: Efficacy and relationship with PD-L1 expression PA Ott, E Elez, S Hiret, DW Kim, RA Moss, T Winser, SS Yuan, ... JOURNAL OF THORACIC ONCOLOGY 10 (9), S193-S193, 2015 | 26 | 2015 |
| 500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028 PA Ott, SA Piha-Paul, P Munster, MJ Pishvaian, E Van Brummelen, ... European Journal of Cancer 3 (51), S102, 2015 | 25 | 2015 |
| Pembrolizumab (MK-3475) in patients with extensive-stage small cell lung cancer: Preliminary safety and efficacy results from KEYNOTE-028 PA Ott, MEE Fernandez, S Hiret, DW Kim, RA Moss, T Winser, S Yuan, ... J Clin Oncol 33 (15S), 400s, 2015 | 15 | 2015 |
| Variable selection for covariate‐adjusted semiparametric inference in randomized clinical trials S Yuan, HH Zhang, M Davidian Statistics in Medicine 31 (29), 3789-3804, 2012 | 15 | 2012 |
| Periodic benefit-risk assessment using Bayesian stochastic multi-criteria acceptability analysis K Li, SS Yuan, W Wang, SS Wan, P Ceesay, JF Heyse, S Mt-Isa, S Luo Contemporary clinical trials 67, 100-108, 2018 | 11 | 2018 |
| On group sequential enrichment design for basket trial SS Yuan, A Chen, L He, C Chen, CK Gause, RA Beckman Statistics in Biopharmaceutical Research 8 (3), 293-306, 2016 | 11 | 2016 |
| Efficiency of a randomized confirmatory basket trial design constrained to control the family wise error rate by indication L He, Y Ren, H Chen, D Guinn, D Parashar, C Chen, SS Yuan, ... Statistical Methods in Medical Research 31 (7), 1207-1223, 2022 | 9 | 2022 |
| Single-agent pembrolizumab for patients with malignant pleural mesothelioma (MPM) EW Alley, JHM Schellens, A Santoro, K Beckey, SS Yuan, J Cheng, ... JOURNAL OF THORACIC ONCOLOGY 10 (9), S195-S195, 2015 | 9 | 2015 |
| Bridging blinded and unblinded analysis for ongoing safety monitoring and evaluation LA Lin, Y Zhan, H Li, SS Yuan, G Ball, W Wang Contemporary Clinical Trials 83, 81-87, 2019 | 7 | 2019 |
| Association of minimal residual disease negativity rates with progression free survival in frontline therapy trials for newly diagnosed multiple myeloma: a meta-analysis J Ficek, E Kalaitzaki, SS Yuan, A Tosolini, L Du, BE Kremer, K Davy, ... Clinical Lymphoma Myeloma and Leukemia 23 (5), e213-e221, 2023 | 5 | 2023 |
| Application of estimand framework in ICH E9 (R1) to safety evaluation X Wang, P Yang, SS Yuan, WWB Wang Journal of Biopharmaceutical Statistics 33 (4), 476-487, 2023 | 4 | 2023 |
